AU2012261869B2 - Long-acting GLP-1/Glucagon receptor agonists - Google Patents
Long-acting GLP-1/Glucagon receptor agonists Download PDFInfo
- Publication number
- AU2012261869B2 AU2012261869B2 AU2012261869A AU2012261869A AU2012261869B2 AU 2012261869 B2 AU2012261869 B2 AU 2012261869B2 AU 2012261869 A AU2012261869 A AU 2012261869A AU 2012261869 A AU2012261869 A AU 2012261869A AU 2012261869 B2 AU2012261869 B2 AU 2012261869B2
- Authority
- AU
- Australia
- Prior art keywords
- oxm
- peg
- conjugate
- another embodiment
- fms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492448P | 2011-06-02 | 2011-06-02 | |
| US61/492,448 | 2011-06-02 | ||
| US201261624589P | 2012-04-16 | 2012-04-16 | |
| US61/624,589 | 2012-04-16 | ||
| PCT/US2012/040744 WO2012167251A1 (en) | 2011-06-02 | 2012-06-04 | Long-acting glp-1/glucagon receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012261869A1 AU2012261869A1 (en) | 2014-01-16 |
| AU2012261869B2 true AU2012261869B2 (en) | 2017-01-05 |
Family
ID=47259955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012261869A Active AU2012261869B2 (en) | 2011-06-02 | 2012-06-04 | Long-acting GLP-1/Glucagon receptor agonists |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140349922A1 (enExample) |
| EP (1) | EP2714070B1 (enExample) |
| JP (1) | JP6182134B2 (enExample) |
| KR (1) | KR102092206B1 (enExample) |
| CN (1) | CN104023739A (enExample) |
| AU (1) | AU2012261869B2 (enExample) |
| BR (1) | BR112013030933A2 (enExample) |
| CA (1) | CA2837710C (enExample) |
| CL (1) | CL2013003450A1 (enExample) |
| CO (1) | CO6980619A2 (enExample) |
| EA (1) | EA201391764A1 (enExample) |
| ES (1) | ES2981891T3 (enExample) |
| HK (1) | HK1201478A1 (enExample) |
| IL (1) | IL229732B (enExample) |
| MX (2) | MX386803B (enExample) |
| SG (1) | SG10201606243YA (enExample) |
| WO (1) | WO2012167251A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| CN104684576B (zh) * | 2012-06-04 | 2019-08-06 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
| EA033788B1 (ru) | 2012-11-20 | 2019-11-26 | Opko Biologics Ltd | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) * | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| CN107438623B (zh) | 2014-12-10 | 2023-07-14 | Opko生物科学有限公司 | 长效的ctp修饰的生长激素多肽的制备方法 |
| MX2017015375A (es) * | 2015-05-29 | 2018-06-19 | Opko Biologics Ltd | Variantes de oxintomodulina pegilada. |
| HUE055449T2 (hu) | 2015-06-19 | 2021-11-29 | Opko Biologics Ltd | Hosszú hatástartamú koagulációs faktorok és eljárások ezek elõállítására |
| TW201706291A (zh) * | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| WO2017075583A2 (en) * | 2015-10-30 | 2017-05-04 | The Research Foundation For The State University Of New York | Oxyntomodulin analogs and methods of making and using same |
| CN113546159B (zh) * | 2015-12-29 | 2023-09-08 | 派格生物医药(苏州)股份有限公司 | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 |
| US20190160152A1 (en) * | 2016-06-09 | 2019-05-30 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| TW202444744A (zh) | 2016-07-11 | 2024-11-16 | 以色列商歐科生物製品有限公司 | 長效型凝血因子及其生產方法 |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| AU2018239037B2 (en) | 2017-03-23 | 2022-05-26 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| WO2019101929A1 (en) | 2017-11-23 | 2019-05-31 | Loewenhielm Peter | Hydrogel composition and its uses |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| WO2020165900A1 (en) | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171920A1 (en) * | 2003-04-08 | 2006-08-03 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| WO2007100535A2 (en) * | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| AU2010225523B2 (en) * | 2009-03-20 | 2012-05-24 | Hanmi Science Co., Ltd. | Method for preparing a site-specific physiologically active polypeptide conjugate |
| AR079344A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
-
2012
- 2012-06-04 MX MX2015011960A patent/MX386803B/es unknown
- 2012-06-04 CA CA2837710A patent/CA2837710C/en active Active
- 2012-06-04 WO PCT/US2012/040744 patent/WO2012167251A1/en not_active Ceased
- 2012-06-04 CN CN201280038726.3A patent/CN104023739A/zh active Pending
- 2012-06-04 JP JP2014513790A patent/JP6182134B2/ja active Active
- 2012-06-04 AU AU2012261869A patent/AU2012261869B2/en active Active
- 2012-06-04 ES ES12793107T patent/ES2981891T3/es active Active
- 2012-06-04 US US14/123,106 patent/US20140349922A1/en active Pending
- 2012-06-04 KR KR1020137035156A patent/KR102092206B1/ko active Active
- 2012-06-04 SG SG10201606243YA patent/SG10201606243YA/en unknown
- 2012-06-04 HK HK15102153.2A patent/HK1201478A1/xx unknown
- 2012-06-04 EP EP12793107.9A patent/EP2714070B1/en active Active
- 2012-06-04 EA EA201391764A patent/EA201391764A1/ru unknown
- 2012-06-04 BR BR112013030933A patent/BR112013030933A2/pt not_active IP Right Cessation
- 2012-06-04 MX MX2013014069A patent/MX346957B/es active IP Right Grant
-
2013
- 2013-11-28 IL IL229732A patent/IL229732B/en unknown
- 2013-12-02 CL CL2013003450A patent/CL2013003450A1/es unknown
- 2013-12-27 CO CO13301132A patent/CO6980619A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171920A1 (en) * | 2003-04-08 | 2006-08-03 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| WO2007100535A2 (en) * | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| US20100144617A1 (en) * | 2006-02-22 | 2010-06-10 | Ranabir Sinha Roy | Oxyntomodulin Derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013030933A2 (pt) | 2018-04-24 |
| IL229732B (en) | 2021-10-31 |
| IL229732A0 (en) | 2014-01-30 |
| MX386803B (es) | 2025-03-19 |
| US20140349922A1 (en) | 2014-11-27 |
| KR20140083929A (ko) | 2014-07-04 |
| CN104023739A (zh) | 2014-09-03 |
| ES2981891T3 (es) | 2024-10-11 |
| KR102092206B1 (ko) | 2020-03-24 |
| MX346957B (es) | 2017-04-06 |
| WO2012167251A1 (en) | 2012-12-06 |
| AU2012261869A1 (en) | 2014-01-16 |
| HK1201478A1 (en) | 2015-09-04 |
| MX2013014069A (es) | 2014-08-22 |
| EA201391764A1 (ru) | 2014-07-30 |
| CO6980619A2 (es) | 2014-06-27 |
| JP6182134B2 (ja) | 2017-08-16 |
| JP2014516993A (ja) | 2014-07-17 |
| EP2714070A4 (en) | 2015-03-04 |
| CA2837710A1 (en) | 2012-12-06 |
| SG10201606243YA (en) | 2016-09-29 |
| CL2013003450A1 (es) | 2015-01-16 |
| EP2714070A1 (en) | 2014-04-09 |
| CA2837710C (en) | 2022-11-08 |
| EP2714070B1 (en) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012261869B2 (en) | Long-acting GLP-1/Glucagon receptor agonists | |
| AU2018201623B2 (en) | Pegylated OXM variants | |
| US10166295B2 (en) | Pegylated OXM variants | |
| AU2016273045B2 (en) | Pegylated oxyntomodulin variants | |
| US20190160152A1 (en) | Long-acting oxyntomodulin formulation and methods of producing and administering same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: OPKO BIOLOGICS LTD. Free format text: FORMER APPLICANT(S): PROLOR BIOTECH INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |